Interestingly, cKD mice attained higher hemoglobin levels following EPO treatment (21.1 ± 0.09 mg/dL) as compared to the hemoglobin levels measured in the EPO-injected controls (20.4 ± 0.2 mg/dL; p < 0.05, Figure 5A). Here, EPO is linked to chronic kidney disease.